Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Pan-cancer whole-genome analyses of metastatic solid tumours.

Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E.

Nature. 2019 Oct 23. doi: 10.1038/s41586-019-1689-y. [Epub ahead of print]

PMID:
31645765
2.

Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.

van Nuland M, Groenland SL, Bergman AM, Steeghs N, Rosing H, Venekamp N, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Oct 14. doi: 10.1038/s41391-019-0179-5. [Epub ahead of print]

PMID:
31611636
3.

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.

Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, Nik-Zainal S, Steenbruggen TG, Tjan-Heijnen VCG, Labots M, van Riel JMGH, Bloemendal HJ, Steeghs N, Lolkema MP, Voest EE, van de Werken HJG, Jager A, Cuppen E, Sleijfer S, Martens JWM.

Nat Genet. 2019 Sep 30. doi: 10.1038/s41588-019-0507-7. [Epub ahead of print]

PMID:
31570896
4.

Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.

Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes DJAR, Desar IME, Reyners AKL, Gelderblom HJ, van Erp NP, Mathijssen RHJ, Huitema ADR, Steeghs N.

Ther Drug Monit. 2019 Oct;41(5):561-567. doi: 10.1097/FTD.0000000000000654.

PMID:
31568233
5.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J.

N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30.

PMID:
31566309
6.

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients.

Verboom MC, Gelderblom H, Kerst JM, Steeghs N, Reyners AKL, Sleijfer S, van der Graaf WTA, van den Hout WB.

Sarcoma. 2019 Jun 2;2019:3234205. doi: 10.1155/2019/3234205. eCollection 2019.

7.

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

Braal CL, Beijnen JH, Koolen SLW, Oomen-de Hoop E, Steeghs N, Jager A, Huitema ADR, Mathijssen RHJ.

J Clin Oncol. 2019 Aug 1;37(22):1980-1981. doi: 10.1200/JCO.19.00418. Epub 2019 Jun 18. No abstract available.

PMID:
31211599
8.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N.

Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318. doi: 10.1007/s00228-019-02704-2. Epub 2019 Jun 7.

PMID:
31175385
9.

Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.

Vlenterie M, Oyen WJ, Steeghs N, Desar IME, Verheijen RB, Koenen AM, Grootjans W, DE Geus-Oei LF, VAN Erp NP, VAN DER Graaf WT.

Anticancer Res. 2019 Mar;39(3):1309-1316. doi: 10.21873/anticanres.13243.

PMID:
30842163
10.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

11.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

12.

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.

Verboom MC, Kloth JSL, Swen JJ, Sleijfer S, Reyners AKL, Steeghs N, Mathijssen RHJ, Gelderblom H, Guchelaar HJ.

Pharmacogenomics J. 2019 Oct;19(5):473-479. doi: 10.1038/s41397-019-0079-z. Epub 2019 Feb 4.

PMID:
30713339
13.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM.

Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.

PMID:
30608567
14.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
15.

Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.

Groenland SL, Katz D, Huitema ADR, Steeghs N.

BMC Cancer. 2018 Dec 3;18(1):1200. doi: 10.1186/s12885-018-5043-9.

16.

Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry.

Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ, Desar IME, van der Graaf WTA, Bonenkamp JJ, Reyners AKL, van Etten B.

Eur J Surg Oncol. 2019 Mar;45(3):410-415. doi: 10.1016/j.ejso.2018.09.013. Epub 2018 Oct 16.

PMID:
30416078
17.

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.

Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW.

Clin Pharmacokinet. 2019 May;58(5):651-658. doi: 10.1007/s40262-018-0719-5.

18.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
19.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

van Broekhoven DLM, Verschoor AJ, van Dalen T, Grünhagen DJ, den Bakker MA, Gelderblom H, Bovee JVMG, Haas RLM, Bonenkamp HJ, van Coevorden F, Ten Oever D, van der Graaf WTA, Flucke UE, Pras E, Reyners AKL, Westermann AM, Oldenburger F, Verhoef C, Steeghs N.

Sarcoma. 2018 Jun 21;2018:5982575. doi: 10.1155/2018/5982575. eCollection 2018.

20.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.

Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2019 Mar;58(3):299-308. doi: 10.1007/s40262-018-0683-0. Review.

PMID:
29862467
21.

Solubility and bioavailability improvement of pazopanib hydrochloride.

Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B.

Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19.

PMID:
29680279
22.

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.

Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL.

Oncotarget. 2018 Feb 14;9(17):13870-13883. doi: 10.18632/oncotarget.24493. eCollection 2018 Mar 2.

23.

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study.

Koldenhof JJ, Lankheet NAG, Steeghs N, Teunissen SCCM, Witteveen PO.

Support Care Cancer. 2018 Aug;26(8):2641-2650. doi: 10.1007/s00520-018-4075-7. Epub 2018 Feb 21.

24.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969
25.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2018 Jun;59(6):973-979. doi: 10.2967/jnumed.117.195800. Epub 2017 Nov 24.

26.

Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.

Farag S, van Coevorden F, Sneekes E, Grunhagen DJ, Reyners AKL, Boonstra PA, van der Graaf WT, Gelderblom HJ, Steeghs N.

Eur J Cancer. 2017 Nov;86:318-325. doi: 10.1016/j.ejca.2017.09.017. Epub 2017 Oct 23.

PMID:
29073582
27.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
28.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1171-1178. doi: 10.1007/s00280-017-3463-x. Epub 2017 Oct 19.

29.

Molecular Tumor Boards: current practice and future needs.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE.

Ann Oncol. 2017 Dec 1;28(12):3070-3075. doi: 10.1093/annonc/mdx528.

PMID:
29045504
30.

Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib.

Farag S, Geus-Oei LF, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, Boonstra PA, Desar I, Gelderblom H, Steeghs N.

J Nucl Med. 2018 Feb;59(2):194-196. doi: 10.2967/jnumed.117.196642. Epub 2017 Sep 28.

31.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

32.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N.

Clin Pharmacokinet. 2018 May;57(5):637-644. doi: 10.1007/s40262-017-0582-9.

33.

Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.

Farag S, van der Kolk LE, van Boven HH, van Akkooi ACJ, Beets GL, Wilmink JW, Steeghs N.

Fam Cancer. 2018 Apr;17(2):247-253. doi: 10.1007/s10689-017-0024-8. Review.

PMID:
28710566
34.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7. Review.

35.

Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.

Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs N.

Eur J Cancer. 2017 May;76:76-83. doi: 10.1016/j.ejca.2017.02.007. Epub 2017 Mar 8.

PMID:
28284172
36.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2017 Sep;56(9):987-997. doi: 10.1007/s40262-017-0510-z. Review.

37.

Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.

Verboom MC, Ouwerkerk J, Steeghs N, Lutjeboer J, Martijn Kerst J, van der Graaf WTA, Reyners AKL, Sleijfer S, Gelderblom H.

Clin Sarcoma Res. 2017 Jan 31;7:2. doi: 10.1186/s13569-017-0066-6. eCollection 2017.

38.

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.

Kloth JSL, Verboom MC, Swen JJ, van der Straaten T, Sleijfer S, Reyners AKL, Steeghs N, Gelderblom H, Guchelaar HJ, Mathijssen RHJ.

Pharmacogenomics J. 2018 Jan;18(1):49-55. doi: 10.1038/tpj.2016.83. Epub 2017 Jan 24.

PMID:
28117434
39.

Individualized Pazopanib Dosing-Response.

Verheijen RB, Huitema AD, Steeghs N.

Clin Cancer Res. 2016 Dec 15;22(24):6299. No abstract available.

40.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N.

Drug Deliv Transl Res. 2017 Feb;7(1):125-131. doi: 10.1007/s13346-016-0346-3.

PMID:
27864786
41.

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.

Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B.

Acta Oncol. 2017 Jan;56(1):88-92. doi: 10.1080/0284186X.2016.1234068. Epub 2016 Nov 14.

PMID:
27838944
42.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, Weeber F, Numan IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP.

Oncologist. 2017 Jan;22(1):33-40. doi: 10.1634/theoncologist.2016-0085. Epub 2016 Sep 23.

43.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD.

Clin Pharmacokinet. 2017 Mar;56(3):293-303. doi: 10.1007/s40262-016-0443-y.

PMID:
27534647
44.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group.

Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. Epub 2016 Jul 28.

45.

Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.

Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema AD, Steeghs N.

Clin Pharmacokinet. 2017 Mar;56(3):287-292. doi: 10.1007/s40262-016-0439-7.

PMID:
27435281
46.

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27.

PMID:
27234642
47.

Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered.

Bijlsma RM, Bredenoord AL, Gadellaa-Hooijdonk CG, Lolkema MP, Sleijfer S, Voest EE, Ausems MG, Steeghs N.

Eur J Hum Genet. 2016 Oct;24(10):1496-500. doi: 10.1038/ejhg.2016.27. Epub 2016 Apr 13.

48.

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, Willems SM, Lolkema MP.

PLoS One. 2016 Feb 26;11(2):e0149405. doi: 10.1371/journal.pone.0149405. eCollection 2016.

49.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD.

Bioanalysis. 2016;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10.

PMID:
26652864
50.

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH.

Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.

Supplemental Content

Loading ...
Support Center